异丁氧基乙酰氯 | 56680-72-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 中文名称: 异丁氧基乙酰氯
• 英文名称: isobutoxy-acetyl chloride
• 英文别名: Isobutyloxyacetylchlorid；Isobutylaetherglykolsaeurechlorid；2-methylpropoxyacetyl chloride；Isobutoxyacetyl chloride；2-(2-methylpropoxy)acetyl chloride
• CAS: 56680-72-9
• 化学式: C₆H₁₁ClO₂
• 分子量: 150.605
• InChiKey: JRJRWVDBFVUPHR-UHFFFAOYSA-N

物化性质

• 沸点：
  48 °C(Press: 10 Torr)
• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  异丁氧基乙酰氯 在 硫酸 作用下， 反应 1.0h， 生成 1-(氯甲氧基)-2-甲基丙烷
  参考文献：
  名称：

  Basavaiah, D.; Rao, P. Dharma; Gowriswari, V. V. L., Synthetic Communications, 1988, vol. 18, # 12, p. 1411 - 1414

  摘要：

  DOI：
• 作为产物：
  描述：

  2-异丁氧基乙酸 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 生成 异丁氧基乙酰氯
  参考文献：
  名称：

  Synthesis of N-[2-(2-methylpropoxy)ethyl]-N-{2-[(4-methoxy) phenylmethylthio]phenyl}-1-pyrrolidineethanamine (E)-2-butenedioate (1:1) salt (CERM 12816): a potential anti-anginal drug

  摘要：

  GERM 12816, which was required for metabolic studies, was labelled with [C-14] in the methylene carbon of the benzyl group. This involved eight steps starting from barium [C-14] carbonate and 4-methoxyphenylmagnesium bromide, with a 20% overall yield. The specific activity was 208 MBq mmol(-1) (5.6 mCi mmol(-1)).

  DOI：

  10.1002/(sici)1099-1344(199803)41:3<181::aid-jlcr68>3.0.co;2-8

文献信息

• Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20050215575A1

  公开（公告）日：2005-09-29

  Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了(7-吡啶基-4-苯基氨基喹唑啉-2-基)-甲醇类似物。这些化合物是配体，可用于调节体内或体外特定受体的活性，并在治疗与人类、驯养伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。提供了用于治疗这些疾病的药物组合物和使用它们的方法，以及用于受体定位研究的这种配体的方法。
• [EN] ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES<br/>[FR] ANALOGUES QUINAZOLINE A SUBSTITUTION D'ARYLALKYLAMINO
  申请人：NEUROGEN CORP

  公开号：WO2005087227A1

  公开（公告）日：2005-09-22

  Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了芳基烷基氨基取代的喹唑啉类似物，其化学式如下，其中变量如本文所述。这些化合物是配体，可用于体内或体外调节特定受体活性，并在治疗人类、驯养伴侣动物和家畜动物中与病理性受体激活相关的疾病方面特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于受体定位研究的这类配体的方法。
• Pyrrole derivatives, their preparation and pharmaceutical compositions
  申请人：Rhone-Poulenc Sante

  公开号：US05102890A1

  公开（公告）日：1992-04-07

  This invention relates to pyrrole derivatives of formula: ##STR1## in which A forms with the pyrrole ring an isoindoline, 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, 2,3,6,7-tetrahydro-5H-[1,4]oxathiino[2,3-c]pyrrole or 2,3,6,7-tetrahydro-5H-[1,4]dithiino[2,3-c]pyrrole ring-system and Hetis naphthyridinyl, pyridyl or quinolyl which is unsubstituted or substituted with halogen, (1 to 4 C) alkyl, (1 to 4 C) alkyloxy, (1 to 4 C) alkylthio or CF.sub.3 and R=(3 to 10 C) straight- or branched-chain alkenyl or alkyl which is unsubstituted or substituted with alkyloxy, alkylthio, (3 to 6 C) cycloalkyl, NH.sub.2, alkylamino, dialkylamino, alkylcarbonylamino, (in which the amino portion is optionally substituted with alkyl), 1- or 2-piperazinyl, piperidyl, piperidino, morpholino, pyrrolidinyl, 1-azetidinyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, (1-piperazinyl)carbonyl, piperidinocarbonyl, (1-pyrrolidinyl)carbonyl, phenyl, pyridyl, 1-imidazolyl, or alternatively R=2- or 3-pyrrolidinyl, 2-, 3- or 4-piperidyl, on the understanding that the alkyl radicals are straight- or branched-chain radicals and contain, except where specifically stated, 1 to 10 C, and that the piperazinyl, piperidino, piperidyl, pyrrolidinyl and azetidinyl radicals can be unsubstituted or substituted at any position with alkyl, alkylcarbonyl, benzyl or hydroxyalkyl, or can alternatively form a lactam group with the nitrogen atom of the ring, and, where they exist, their pharmaceutically acceptable salts and optical isomers, are useful as anxiolytics.

  本发明涉及公式为：## STR1 ##的吡咯衍生物，其中A与吡咯环形成异吲哚啉，6,7-二氢-5H-吡咯[3,4-b]吡嗪，2,3,6,7-四氢-5H-[1,4]噁嗪并[2,3-c]吡咯或2,3,6,7-四氢-5H-[1,4]二噻并[2,3-c]吡咯环系统，Het为萘啉基，吡啶基或喹啉基，未取代或取代卤素，（1至4C）烷基，（1至4C）烷氧基，（1至4C）烷硫基或CF.sub.3，R = （3至10C）直链或支链烯基或烷基，未取代或取代烷氧基，烷硫基，（3至6C）环烷基，NH.sub.2，烷基氨基，二烷基氨基，烷基羰基氨基（其中氨基部分可以选配取代烷基），1-或2-哌嗪基，哌啶基，哌啶基，吗啉基，吡咯烷基，1-氮杂环丙基，氨基甲酰基，烷基甲酰基，二烷基甲酰基，（1-哌嗪基）甲酰基，哌啶基甲酰基，（1-吡咯烷基）甲酰基，苯基，吡啶基，1-咪唑基，或者R = 2-或3-吡咯烷基，2-，3-或4-哌嗪基，其中烷基基团是直链或支链基团，并且除非特别说明，含有1至10C，而哌嗪基，哌啶基，哌啶基，吡咯烷基和氮杂环丙基基团可以未取代或取代任何位置的烷基，烷基甲酰基，苯甲基或羟基烷基，或者可以与环的氮原子形成内酰胺基团，其中，它们的药学上可接受的盐和光学异构体可用作抗焦虑药。
• Arylalkylamino-substituted quinazoline analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20070219203A1

  公开（公告）日：2007-09-20

  Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了取代芘基烷基氨基喹唑啉类似物，其化学式如下：其中变量如本文所述。这些化合物是配体，可用于体内或体外调节特定受体活性，并且在治疗与人类、家养伴侣动物和家畜动物的病理受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的药物组合物和方法，以及使用这些配体进行受体定位研究的方法。
• Blaise; Picard, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1911, vol. 152, p. 269
  作者：Blaise、Picard

  DOI：——

  日期：——